Generation Bio Co. (GBIO) Reports Poor Results for Preclinical Studies for Hemophilia A Program
Robbins LLP is investigating Generation Bio Co. (NASDAQ: GBIO) to determine whether certain Generation Bio officers and directors violated the Securities Exchange Act of 1934 and breached fiduciary duties to shareholders. Generation Bio develops gene therapies for the treatment of rare and prevalent diseases.
On December 14, 2021, Generation Bio issued a press release that “provided an update on factor VIII expression from a series of mouse and companion non-human primate (NHP) studies in hemophilia A, as well as an update on the development of its non-viral genetic medicine platform. Generation Bio’s proprietary genetic medicine technology comprises a closed-ended DNA (ceDNA) delivered via a novel, cell-targeted lipid nanoparticle (ctLNP).” The Company disclosed results that showed that in mice, ceDNA generated peak mean human factor VIII expression of 205% of normal at 2.0 mg/kg, and advised that “[a]dditional optimization is needed to translate the improvement in potency and reduction in variability observed in mice to [non-human primates], and to support nomination of a development candidate for the company’s hemophilia A program[.]” On this news, Generation Bio’s stock price fell $7.91 per share, to close at $5.99 per share on December 14, 2021.
Generation Bio Co. (GBIO) shareholders have legal options. If you own, or have previously owned, shares of Generation Bio Co., contact us for more information about your rights.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.